Figure 2.

Advances in immunotherapy informed by genomic analysis of PDAC tumors. A) Vaccine strategies can take advantage of either natural (Muc1 and ɑ-enolase) or man-made (ɑ-gal) post-translational modifications of self-proteins. B) PDAC tumors express high levels of aberrant surface proteins, which can be targeted by T cells with chimeric antigen receptors (CARs). C) Both immunosuppressive (1&2) and desmoplastic (3&4) features of the PDAC immune environment are being targeted by novel immunotherapies.